IP Library Granted Patent US 12,668,596
Granted Patent B2
US 12,668,596 · App. 18/260,951 · Granted Jun 30, 2026

Process for crystallizing nalmefene hydrochloride

Inventor: C. Frederick M. Huntley (East Greenwich, RI)
Assignee: RHODES TECHNOLOGIES
C07D489/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,668,596
App. No.
18/260,951
Filed
Jul 11, 2023
Granted
Jun 30, 2026
Kind
B2
Art Unit
1699
USPC
546/46
Abstract

The application is directed to an efficient process for crystallizing nalmefene hydrochloride in a hydrated form from an aqueous hydrochloric acid solution (or a mixture) with a high yield.

Claims (27)

1 . A process for crystallizing nalmefene hydrochloride, said process comprising:

mixing a source of nalmefene, water and hydrochloric acid to provide a substantially homogeneous mixture, wherein the hydrochloric acid is present in said substantially homogeneous mixture in an amount sufficient to achieve a final molarity of about 3 M to about 4 M; and

crystallizing said nalmefene hydrochloride from said substantially homogeneous mixture to provide a heterogenous mixture comprising crystalline hydrated form of nalmefene hydrochloride in an acidic aqueous continuous phase.

2 . The process of claim 1 , further comprising filtering said substantially homogeneous mixture to remove trace impurities prior to said crystallizing.

3 . The process of claim 1 , further comprising isolating a crystalline form of nalmefene hydrochloride from said heterogeneous mixture.

4 . The process of claim 1 , wherein said process comprises:

mixing said source of nalmefene in water or aqueous hydrochloric acid at an elevated temperature to obtain a substantially homogeneous mixture; and

crystallizing nalmefene hydrochloride by adding concentrated hydrochloric acid to said substantially homogeneous mixture in an amount sufficient to achieve a final molarity of the hydrochloric acid of from about 3 M to about 4 M, thus providing a heterogeneous mixture comprising a crystalline hydrated form of nalmefene hydrochloride in an acidic aqueous continuous phase.

5 . The process of claim 4 , wherein about 1 ml to about 5 ml of an acidic aqueous continuous phase is provided for every gram of said source of nalmefene.

6 . The process of claim 4 , further comprising filtering said substantially homogeneous mixture to remove trace solid impurities.

7 . The process of claim 4 , wherein said concentrated hydrochloric acid is added to said substantially homogeneous mixture in an amount to achieve a final molarity of about 3.5 M.

8 . The process of claim 1 , wherein said process comprises:

mixing said source of nalmefene in about 3 M to about 4 M hydrochloric acid at an elevated temperature to obtain a substantially homogeneous mixture; and

cooling said substantially homogeneous mixture or allowing said substantially homogeneous mixture to cool to a reduced temperature to provide a heterogeneous mixture comprising crystalline hydrated form of nalmefene hydrochloride in an acidic aqueous continuous phase,

wherein about 1 ml to about 5 ml of an acidic aqueous continuous phase is provided for every gram of said source of nalmefene.

9 . The process of claim 4 , wherein said crystalline hydrated form of nalmefene hydrochloride is isolated from said heterogeneous mixture.

10 . The process of claim 1 , wherein said source of nalmefene is nalmefene free base.

11 . The process of claim 1 , wherein said source of nalmefene is an acid salt of nalmefene.

12 . The process of claim 11 , wherein said source of nalmefene is nalmefene hydrochloride.

13 . The process of claim 12 , wherein said source of nalmefene is a hydrated form of nalmefene hydrochloride.

14 . The process of claim 13 , wherein said hydrated form of nalmefene hydrochloride is nalmefene hydrochloride monohydrate or nalmefene hydrochloride dihydrate.

15 . The process of claim 4 , wherein said source of nalmefene is dissolved at a temperature of from about 50° C. to about 90° C.

16 . The process of claim 4 , further comprising allowing said substantially homogeneous mixture to cool to a reduced temperature.

17 . The process of claim 16 , further comprising cooling said mixture to about 0 to 5° C., and isolating said crystalline hydrated form of nalmefene hydrochloride by filtration.

18 . The process of claim 17 , further comprising steps of washing said isolated crystalline hydrated form of nalmefene hydrochloride with 3 M hydrochloric acid, and drying.

19 . The process of claim 1 , wherein said crystalline hydrated form of nalmefene hydrochloride is crystalline nalmefene hydrochloride monohydrate.

20 . The process of claim 1 , wherein said crystalline hydrated form of nalmefene hydrochloride is crystalline nalmefene hydrochloride dihydrate.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2026
From: RHODES TECHNOLOGIES
To: KNOA PHARMA LLC
Reel/Frame 075838/0956 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2025
From: HUNTLEY, C. FREDERICK M.
To: RHODES TECHNOLOGIES
Reel/Frame 071649/0644 →
Continuity (2)
Provisional Application 63142791 · Jan 28, 2021
Related Publication 20240109907A1 · Apr 4, 2024
References Cited (17)
US 4535157A · Meltzer et al. · 1985 [cited by applicant]
US 4751307A · White et al. · 1988 [cited by applicant]
US 8598352B2 · De Faveri et al. · 2013 [cited by applicant]
US 8754217B2 · Lopez De Diego et al. · 2014 [cited by applicant]
US 20140296525A1 · De Faveri et al. · 2014 [cited by applicant]
CN 106167492A · 2016 [cited by applicant]
RU 2712232C1 · 2020 [cited by applicant]
WO WO2010136039A1 · 2010 [cited by applicant]
WO WO2013083685A1 · 2013 [cited by applicant]
Karhuvaara, S., et al., “Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study,” Alcohol. Clin. Exp. Res. 31(7):1179-1187, W… [cited by applicant]
Hahn, E.F., et al., “Narcotic antagonists. 4. Carbon-6 derivatives of N-substituted noroxymorphones as narcotic antagonists,” J. Med. Chem. 18(3):259-262, ACS Publications, United States (1975). [cited by applicant]
Caira, M.R., et al., “Preparation and crystal characterization of a polymorph, a monohydrate, and an ethyl acetate solvate of the antifungal fluconazole,” J. Pharm. Sci. 93(3):601-611, Wiley-Liss, Inc., United States (M… [cited by applicant]
Van Tonder, E.C., et al., “Preparation and physicochemical characterization of 5 niclosamide solvates and 1 hemisolvate,” AAPS Pharm Sci Tech 5(1):E12, Springer International Publishing AG, Switzerland (2004) (10 pages). [cited by applicant]
Bingham, A. L., et al., “Over one hundred solvates of sulfathiazole,” Chemical Communications (7):603-604, Royal Society of Chemistry, United Kingdom (2001). [cited by applicant]
“Molecular Structure, Properties, and States of Matter” in Remington's Pharmaceutical Sciences, Chapter 13, pp. 172-174,18th ed, Gennaro, A. R. ed., Mack Publishing Co., Easton PA, United States (1990). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/014104, European Patent Office, Netherlands, mailed on Apr. 8, 2022, 10 pages. [cited by applicant]
Brittain, H., “Nalmefene Hydrochloride,” in Analytical Profiles of Drug Substances and Excipients, vol. 24, pp. 351-395, Academic Press Inc., United States (1996). [cited by applicant]